Delineation of a Conserved Arrestin-Biased Signaling Repertoire In Vivo

Biased G protein–coupled receptor agonists engender a restricted repertoire of downstream events from their cognate receptors, permitting them to produce mixed agonist-antagonist effects in vivo. While this opens the possibility of novel therapeutics, it complicates rational drug design, since the in vivo response to a biased agonist cannot be reliably predicted from its in cellula efficacy. We have employed novel informatic approaches to characterize the in vivo transcriptomic signature of the arrestin pathway-selective parathyroid hormone analog [d-Trp12, Tyr34]bovine PTH(7-34) in six different murine tissues after chronic drug exposure. We find that [d-Trp12, Tyr34]bovine PTH(7-34) elicits a distinctive arrestin-signaling focused transcriptomic response that is more coherently regulated across tissues than that of the pluripotent agonist, human PTH(1-34). This arrestin-focused network is closely associated with transcriptional control of cell growth and development. Our demonstration of a conserved arrestin-dependent transcriptomic signature suggests a framework within which the in vivo outcomes of arrestin-biased signaling may be generalized.

[1]  M. Bouvier,et al.  Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.

[2]  L. Luttrell,et al.  Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.

[3]  Qiong Shi,et al.  Role of β-arrestin 1 in the metastatic progression of colorectal cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Stuart Maudsley,et al.  VENNTURE–A Novel Venn Diagram Investigational Tool for Multiple Pharmacological Dataset Analysis , 2012, PloS one.

[5]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[6]  Duncan J. Watts,et al.  Collective dynamics of ‘small-world’ networks , 1998, Nature.

[7]  T. Kenakin.  Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.

[8]  Stuart Maudsley,et al.  The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  S. Chellappan,et al.  Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. , 2006, The Journal of clinical investigation.

[10]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[11]  J. Desvignes,et al.  Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[12]  J. Benovic,et al.  Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer , 2009, Proceedings of the National Academy of Sciences.

[13]  Gunnar E. Carlsson,et al.  Topology and data , 2009 .

[14]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[15]  M. Donowitz,et al.  Na+/H+ exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling , 2002, Nature.

[16]  Peng-hui Zhang,et al.  Elevated b-arrestin1 expression correlated with risk stratification in acute lymphoblastic leukemia , 2011 .

[17]  H. Jüppner,et al.  Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. , 1993, Endocrinology.

[18]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[19]  R. Lefkowitz,et al.  β-Arrestin2 mediates the initiation and progression of myeloid leukemia , 2012, Proceedings of the National Academy of Sciences.

[20]  Stuart Maudsley,et al.  Minimal Peroxide Exposure of Neuronal Cells Induces Multifaceted Adaptive Responses , 2010, PloS one.

[21]  E. Garrett-Mayer,et al.  Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. , 2008, Cancer research.

[22]  S. Gammeltoft,et al.  Quantitative Phosphoproteomics Dissection of Seven-transmembrane Receptor Signaling Using Full and Biased Agonists* , 2010, Molecular & Cellular Proteomics.

[23]  T. Kenakin,et al.  Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. , 2011, Methods in molecular biology.

[24]  M. Janech,et al.  The β-Arrestin Pathway-selective Type 1A Angiotensin Receptor (AT1A) Agonist [Sar1,Ile4,Ile8]Angiotensin II Regulates a Robust G Protein-independent Signaling Network* , 2011, The Journal of Biological Chemistry.

[25]  R. Lefkowitz,et al.  Therapeutic potential of β-arrestin- and G protein-biased agonists. , 2011, Trends in molecular medicine.

[26]  G. Segre,et al.  Na+/H+ exchanger-regulatory factor 1 mediates inhibition of phosphate transport by parathyroid hormone and second messengers by acting at multiple sites in opossum kidney cells. , 2003, Molecular endocrinology.

[27]  G. Carlsson,et al.  Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival , 2011, Proceedings of the National Academy of Sciences.

[28]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[29]  L. Luttrell.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. , 2014, Molecular endocrinology.

[30]  L. Hunyady,et al.  Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Luttrell,et al.  Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics. , 2012, Mini reviews in medicinal chemistry.

[32]  R. Lefkowitz,et al.  Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[33]  Stuart Maudsley,et al.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. , 2013, Molecular endocrinology.

[34]  Stuart Maudsley,et al.  Systems analysis of arrestin pathway functions. , 2013, Progress in molecular biology and translational science.

[35]  K. Chun,et al.  The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. , 2009, Carcinogenesis.

[36]  G. Mills,et al.  β-Arrestin/Ral Signaling Regulates Lysophosphatidic Acid–Mediated Migration and Invasion of Human Breast Tumor Cells , 2009, Molecular Cancer Research.

[37]  Mihaela E. Sardiu,et al.  Conserved abundance and topological features in chromatin‐remodeling protein interaction networks , 2015, EMBO reports.

[38]  R. Lefkowitz,et al.  A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.

[39]  Y. Peterson,et al.  Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity. , 2013, Methods in Enzymology.

[40]  Annamaria Biroccio,et al.  β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis , 2009, Proceedings of the National Academy of Sciences.

[41]  Qiong Shi,et al.  Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Luttrell,et al.  ␤-arrestin-and G Protein Receptor Kinase- Mediated Calcium-sensing Receptor Desensitization , 2022 .

[43]  Hongyu Chen,et al.  Plurigon: three dimensional visualization and classification of high-dimensionality data , 2013, Front. Physiol..

[44]  Kurt Wüthrich,et al.  Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.

[45]  P. Y. Lum,et al.  Extracting insights from the shape of complex data using topology , 2013, Scientific Reports.

[46]  J. L. Hansen,et al.  Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. , 2012, Nature chemical biology.

[47]  Peng-hui Zhang,et al.  Elevated β-arrestin1 expression correlated with risk stratification in acute lymphoblastic leukemia , 2011, International journal of hematology.

[48]  R. Lefkowitz,et al.  β-Arrestin-mediated receptor trafficking and signal transduction. , 2011, Trends in pharmacological sciences.

[49]  W. Wood,et al.  Euglycemic Agent-mediated Hypothalamic Transcriptomic Manipulation in the N171–82Q Model of Huntington Disease Is Related to Their Physiological Efficacy* , 2012, The Journal of Biological Chemistry.

[50]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.